Literature DB >> 8222811

Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases.

A Sanchez-Armengol1, F Rodriguez-Panadero.   

Abstract

STUDY
OBJECTIVE: To find out whether patients with different types of metastatic pleural carcinomas have significant differences in survival, as related to pleural fluid glucose and pH. A second objective was to evaluate the outcome of talc poudrage for pleurodesis.
DESIGN: Cohort analytic prospective study; follow-up of patients from thoracoscopic diagnosis and evaluation to death.
SETTING: Pulmonary department at a referral medical center. PATIENTS: One hundred twenty-five patients with metastatic pleural carcinoma diagnosed by thoracoscopy were evaluated prospectively. One patient was lost to follow-up.
INTERVENTIONS: Thoracoscopy was performed in every patient, with talc pleurodesis performed at the end of each procedure. MEASUREMENTS AND
RESULTS: On the same day as thoracoscopy or the previous day, glucose levels and pH of both the blood and pleural fluid were determined. The outcome of talc poudrage was that pleural effusions were controlled in 104 out of 119 patients (87 percent). Pleurodesis failed in 43 percent (6/14) of the patients with a pleural fluid pH lower than 7.20, as opposed to 9 percent (8/92) of failures in patients with a pH above this limit (p < 0.01). Average survival was as follows: nonsmall cell lung cancer (n = 40), 4.3 months (range, 1 to 15 months); small cell lung cancer (n = 8), 3.7 months (1 to 12 months); breast carcinoma (n = 30), 7.4 months (1 to 29 months); and ovarian carcinoma (n = 8), 9.4 months (1 to 29 months). There was a significant difference in survival between patients with breast carcinoma and patients with cancer not sensitive to chemotherapy (7.4 vs 4.7 months; p < 0.02), although the pleural tumor lesion rating was even greater in the first group. We found no significant differences between lung carcinomas and those from other origins. Patients with a low pleural fluid glucose level and low pH had significantly shorter survival than the group with high glucose and high pH levels (1.9 vs 5.7 months, respectively; p < 0.005).
CONCLUSIONS: We confirmed our previous data demonstrating poor survival in patients with pleural effusions with low glucose and pH levels. The outcome of talc pleurodesis correlated to these same parameters. These results apply to all kinds of metastatic pleural carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222811     DOI: 10.1378/chest.104.5.1482

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Pleural fluid findings as prognostic factors for malignant pleural mesothelioma.

Authors:  Tanseli Efeoglu Gonlugur; Ugur Gonlugur
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

2.  Corynebacterium parvum for malignant pleural effusions.

Authors:  V Foresti
Journal:  Thorax       Date:  1995-01       Impact factor: 9.139

3.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Authors:  Carolyn M Dresler; Jemi Olak; James E Herndon; William G Richards; Ernest Scalzetti; Stewart B Fleishman; Kemp H Kernstine; Todd Demmy; David M Jablons; Leslie Kohman; Thomas M Daniel; George B Haasler; David J Sugarbaker
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

4.  Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study.

Authors:  Marta Korsic; Sonja Badovinac; Branka Cucevic; Zoran Janevski
Journal:  Wien Klin Wochenschr       Date:  2015-04-10       Impact factor: 1.704

5.  Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases.

Authors:  Nobuaki Matsubara; Kuniaki Itoh; Hirofumi Mukai; Shunji Nagai
Journal:  Int J Clin Oncol       Date:  2011-10-07       Impact factor: 3.402

6.  Tumor type influences the effectiveness of pleurodesis in malignant effusions.

Authors:  Silvia Bielsa; Paula Hernández; Francisco Rodriguez-Panadero; Teresa Taberner; Antonieta Salud; José M Porcel
Journal:  Lung       Date:  2011-02-18       Impact factor: 2.584

Review 7.  Malignant pleural effusions: appropriate treatment approaches.

Authors:  Yener Aydin; Atila Turkyilmaz; Yavuz Selim Intepe; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2009-12

8.  Management of malignant pleural effusions with indwelling pleural catheters or talc pleurodesis.

Authors:  Nadim Srour; Kayvan Amjadi; Alan Forster; Shawn Aaron
Journal:  Can Respir J       Date:  2013 Mar-Apr       Impact factor: 2.409

Review 9.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

10.  Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.

Authors:  Erminia Massarelli; Amir Onn; Edith M Marom; Christine M Alden; Diane D Liu; Hai T Tran; Barbara Mino; Ignacio I Wistuba; Saadia A Faiz; Lara Bashoura; George A Eapen; Rodolfo C Morice; J Jack Lee; Waun K Hong; Roy S Herbst; Carlos A Jimenez
Journal:  Clin Lung Cancer       Date:  2014-05-14       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.